$DMRA News

Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35

Damora Therapeutics: Well-Funded Moonshot For CALR Mutations

Damora Therapeutics Says On Track For First Regulatory Submission For DMR-001 In Mid-2026

Damora Therapeutics Q1 EPS $(0.62) Misses $(0.40) Estimate

Damora Therapeutics CFO Lori Firmani Steps Down, Effective May 1

RBC Capital Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $40

What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?

How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%

Damora Therapeutics (DMRA) Overhauls Leadership: Is Its Capital Strategy About To Quietly Shift?

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evercore ISI Group Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $46

Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

Damora Therapeutics Appoints Jennifer Jarrett As President And CEO, Effective March 30; Names Peter Harwin Chairman of The Board

Damora Therapeutics Appoints Jennifer Jarrett As President And CEO, Effective March 30; Names Peter Harwin Chairman of The Board

Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Damora Therapeutics FY2025 EPS $3.98 Up From FY2024 EPS $(18.53)

Galecto Changes Name To Damora Therapeutics, Symbol To DMRA, Effective March 10

UBS Initiates Coverage On Galecto with Buy Rating, Announces Price Target of $45

Guggenheim Maintains Buy on Galecto, Raises Price Target to $40

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million